# Watrium AS

> Watrium AS is a VC fund in Oslo backing Medical and Chemical. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Oslo, Norway
- Total investments: 6
- Last investment: Sep 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/watrium-as
- Website: http://watrium.no/

Watrium AS is a VC fund in Oslo focused on Medical and Chemical. Simplicity is the ultimate sophistication.

## Contacts

5 contacts available for Watrium AS. Shizune tracks 1 team members at Watrium AS. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/watrium-as?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 17% |
| Chemical | 1 | 17% |
| Robotics | 1 | 17% |
| Health Care | 1 | 17% |
| Life Science | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 17% |
| Series B | 1 | 17% |
| Series D | 1 | 17% |
| Funding Round | 1 | 17% |
| Venture - Series Unknown | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Norway | 1 | 17% |
| Sweden | 1 | 17% |
| United Kingdom | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anders Christopher Garmann Wilhelmsen | CEO | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CMR Surgical | CMR Surgical develops and manufactures robotic surgical systems designed to enhance precision and efficiency in minimally invasive surgery. Its primary product, Versius, is a versatile and modular robotic system that supports various surgical procedures.Versius is designed to mimic the human arm's flexibility while offering a compact andergonomic design. It integrates with hospital workflows and provides data-driven insights to support surgical performance. CMR Surgical collaborates with healthcare professionals to ensure that its technology meets clinical needs and improves patient outcomes. | $163.9M | Series D | Sep 20, 2023 |  |
| Oncoinvent | Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns. | $29.2M | Venture - Series Unknown | Jun 29, 2021 |  |
| CMR Surgical | CMR Surgical develops and manufactures robotic surgical systems designed to enhance precision and efficiency in minimally invasive surgery. Its primary product, Versius, is a versatile and modular robotic system that supports various surgical procedures.Versius is designed to mimic the human arm's flexibility while offering a compact andergonomic design. It integrates with hospital workflows and provides data-driven insights to support surgical performance. CMR Surgical collaborates with healthcare professionals to ensure that its technology meets clinical needs and improves patient outcomes. | $600M | Series D | Jun 28, 2021 |  |
| CMR Surgical | CMR Surgical develops and manufactures robotic surgical systems designed to enhance precision and efficiency in minimally invasive surgery. Its primary product, Versius, is a versatile and modular robotic system that supports various surgical procedures.Versius is designed to mimic the human arm's flexibility while offering a compact andergonomic design. It integrates with hospital workflows and provides data-driven insights to support surgical performance. CMR Surgical collaborates with healthcare professionals to ensure that its technology meets clinical needs and improves patient outcomes. | $96.9M | Series B | Jun 04, 2018 |  |
| CMR Surgical | CMR Surgical develops and manufactures robotic surgical systems designed to enhance precision and efficiency in minimally invasive surgery. Its primary product, Versius, is a versatile and modular robotic system that supports various surgical procedures.Versius is designed to mimic the human arm's flexibility while offering a compact andergonomic design. It integrates with hospital workflows and provides data-driven insights to support surgical performance. CMR Surgical collaborates with healthcare professionals to ensure that its technology meets clinical needs and improves patient outcomes. | $26M | Series A | Sep 18, 2017 |  |
| GLO | glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who haspublished more than 500 papers related to this technology.glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications.glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications.glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized.glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications. | $23.3M |  | Aug 09, 2017 |  |

6 of 6 investments shown.

## Co-investors
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 4 deals together
- [Escala Capital](https://shizune.co/investors/profile/escala-capital) — VC Fund, 3 deals together
- [LGT group](https://shizune.co/investors/profile/lgt-group) — VC Fund, 3 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 2 deals together
- [Lightrock](https://shizune.co/investors/profile/lgt-lightstone) — VC Fund, 2 deals together
- [Lightrock](https://shizune.co/investors/profile/lightrock) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Watrium AS invest in?

Watrium AS invests primarily in Medical, Chemical and Robotics startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Watrium AS?

Public channels for Watrium AS include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Watrium AS?

The team at Watrium AS includes Anders Christopher Garmann Wilhelmsen (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co